On April 11, 2022, James O'Leary, M.D. tendered his resignation as Chief Medical Officer of Fusion Pharmaceuticals Inc. (the Company") effective June 30, 2022 (Exit Date"). Effective immediately, Dr. Joanne Schindler, who currently serves as Vice President, Medical Director, has been promoted to Executive Vice President, Medical Director & Clinical Development. Dr. O'Leary is expected to transition to Dr. Schindler full responsibility for all of the Company's clinical trials and for the day-to-day operations of the clinical and regulatory functions prior to his Exit Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.3 USD | 0.00% | +1.00% | +121.64% |
Mar. 20 | Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca | MT |
Mar. 20 | Fusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
- Stock
- Equities
- Stock FUSN PHAR - Nasdaq
- News FUSN PHAR
- Fusion Pharmaceuticals Inc. Announces Executive Changes